Skip to main content
AbbVie Inc. logo

AbbVie Inc. — Investor Relations & Filings

Ticker · ABBV ISIN · US00287Y1091 LEI · FR5LCKFTG8054YNNRU85 US Manufacturing
Open in API
Filings indexed 1,570 across all filing types
Latest filing 2026-06-01 Regulatory Filings
Country US United States of America
Listing US ABBV

About AbbVie Inc.

https://www.abbvie.com/

AbbVie Inc. is a global, research-based biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative medicines and therapeutic solutions. The company's mission is to address complex health issues and make a significant impact on patients' lives by combining advanced science with deep expertise. AbbVie develops treatments across various therapeutic areas, aiming to solve serious health challenges. In addition to its proprietary product pipeline, the company also offers contract manufacturing services for both small molecules and biologics, supporting other pharmaceutical partners in their development and production needs.

Recent filings

Filing Released Lang Actions
FORM SD
Regulatory Filings Classification · 94% confidence The document is a Form SD (“Specialized Disclosure Report”) filed with the SEC under Rule 13p-1 to disclose conflict minerals information. It is not an annual or quarterly report, proxy, earnings release, management discussion, or other specific category listed. It is a standard regulatory filing for specialized disclosure. Therefore it falls under the fallback “Regulatory Filings” category (RNS).
2026-06-01 English
8-K - AbbVie Inc. (0001551152) (Filer)
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is a SEC Form 8-K filed under Item 5.07 “Submission of Matters to a Vote of Security Holders,” detailing vote counts for director elections and other proposals at the 2026 Annual Meeting. This clearly constitutes official results from a shareholder vote, matching the Declaration of Voting Results & Voting Rights Announcements category.
2026-05-12 English
10-Q - AbbVie Inc. (0001551152) (Filer)
Interim / Quarterly Report Q1 2026
2026-05-08 English
8-K - AbbVie Inc. (0001551152) (Filer)
Regulatory Filings Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC, which is used for reporting unscheduled material events or corporate changes. The text indicates that the report announces the issuance of a press release with financial results for the first quarter ended March 31, 2026, but does not contain the financial results itself. The document is only 3434 characters long and primarily serves to furnish the press release as an exhibit. This matches the characteristics of a Regulatory Filing (RNS) rather than an Earnings Release (ER) or Interim Report (IR), since the actual financial data is in the press release exhibit, not in the main document. Therefore, the classification is Regulatory Filings (RNS).
2026-04-29 English
8-K - AbbVie Inc. (0001551152) (Filer)
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report used to announce unscheduled material events or corporate changes. The content focuses on preliminary financial results and guidance updates for the first quarter of 2026, including acquired IPR&D and milestones expense impact on earnings per share. It does not contain full financial statements or comprehensive financial analysis typical of an Interim/Quarterly Report (IR). Instead, it provides a brief update on earnings guidance and financial condition. The document also includes a cautionary forward-looking statement and references an exhibit with additional guidance details. Given the nature of the Form 8-K and the content being a financial update rather than a full report, the classification aligns best with a Capital/Financing Update (CAP), which covers updates on financial condition and earnings guidance. The document is not a full earnings release (ER) as it lacks key highlights and final results, nor is it a Management Discussion and Analysis (MDA) or Annual Report (10-K). Therefore, the most appropriate classification is CAP with high confidence.
2026-04-03 English
SCHEDULE 13G/A - AbbVie Inc. (0001551152) (Subject)
Major Shareholding Notification
2026-03-26 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.